A Phase I, Open-Label, Parallel-Group, Single Dose, Non-Randomized Study To Compare The Pharmacokinetics Of Each Individual Component (Topiramate And Phentermine) Of The Combination Product Vi-0521 In Subjects With Mild, Moderate And Severe Renal Impairment To Subjects With Normal Renal Function.
Phase of Trial: Phase I
Latest Information Update: 03 Feb 2010
At a glance
- Drugs Phentermine/topiramate (Primary)
- Indications Obesity; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors VIVUS
- 04 Dec 2009 Actual end date (Jul 2009) added as reported by ClinicalTrials.gov.
- 04 Dec 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 09 Mar 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.